Takeda's takhzyro® (lanadelumab) approved in japan for prophylaxis against acute attacks of hereditary angioedema (hae)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that it has received approval from the ministry of health, labour and welfare (mhlw) for takhzyro® (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older in japan.1 hereditary angioedema (hae) is a rare genetic disorder that results in recurring attacks of oedema – swelling – in va
TAK Ratings Summary
TAK Quant Ranking